Cagri peptide combined with retatrutide represents one of the most discussed frontiers in obesity medicine, yet it remains an entirely investigational concept with no approved clinical use in the UK. Cagrilintide is a long-acting amylin analogue, whilst retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon pathways. Together, their complementary mechanisms have generated significant scientific interest. This article explains how each agent works, what the current evidence shows, the safety considerations patients should understand, and how to access emerging obesity treatments safely through regulated NHS and clinical trial pathways.

What Are Cagrilintide and Retatrutide and How Do They Work?

Cagrilintide is a long-acting amylin analogue that reduces appetite and slows gastric emptying, whilst retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist designed to reduce appetite and increase energy expenditure.

Cagrilintide and retatrutide are two investigational peptide-based medicines currently being studied for the treatment of obesity and related metabolic conditions. Both work by targeting specific receptors involved in appetite regulation, glucose metabolism, and energy balance, but they do so through distinct hormonal pathways.

Cagrilintide is a long-acting analogue of amylin, a hormone naturally co-secreted with insulin from the pancreatic beta cells. Amylin is a pancreatic hormone — not an incretin — that plays a key role in slowing gastric emptying, reducing glucagon secretion, and promoting satiety. By mimicking and prolonging these effects, cagrilintide helps reduce caloric intake and supports weight loss. It is designed for once-weekly subcutaneous injection.

Retatrutide, developed by Eli Lilly, is a novel triple agonist that simultaneously activates three receptors:

• GLP-1 (glucagon-like peptide-1) receptor — reduces appetite and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptor — enhances insulin secretion; effects on fat metabolism in humans are still being characterised and should not be overstated

• Glucagon receptor — increases energy expenditure and promotes fat breakdown, though it may also raise hepatic glucose output; the net metabolic effect is under active investigation

Retatrutide has been studied as a once-weekly subcutaneous injection in clinical trials. This triple-receptor mechanism distinguishes it from existing approved agents such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist). The combined activation of all three pathways is hypothesised to produce more pronounced and sustained weight reduction, though the long-term clinical implications of each receptor's contribution remain to be fully established. Neither agent is currently approved for routine clinical use in the UK, and both remain under active investigation.

Combining These Peptides: Rationale and Mechanism of Action

The combination of cagrilintide with retatrutide is entirely hypothetical; no clinical trial data exist for this pairing, though their complementary amylin and incretin-based mechanisms provide a theoretical scientific rationale.

The scientific rationale for combining cagrilintide with retatrutide lies in the complementary nature of their mechanisms. Whilst retatrutide targets GLP-1, GIP, and glucagon receptors to reduce appetite and increase energy expenditure, cagrilintide acts via the amylin receptor pathway — a distinct hormonal axis. Targeting multiple hormonal systems simultaneously may offer additive benefits in weight reduction and metabolic improvement that neither agent could achieve alone.

Amylin and GLP-1 pathways are known to interact within the central nervous system, particularly in the hypothalamus and brainstem — areas critical to hunger and satiety signalling. Preclinical studies have suggested that combining amylin receptor agonism with GLP-1–based therapies produces greater reductions in food intake and body weight than either approach in isolation, and early clinical data from the CagriSema programme (cagrilintide combined with semaglutide) has provided some supporting evidence in humans.

It is important to note that the specific combination of cagrilintide with retatrutide as a co-administered regimen is entirely hypothetical at this stage. There are no published clinical trial data evaluating this pairing, and it does not exist as a named investigational product or registered trial programme. Most published combination data involves cagrilintide paired with semaglutide (the combination known as CagriSema, being developed by Novo Nordisk). The theoretical extension of this rationale to retatrutide is scientifically plausible but remains exploratory. Patients should be aware that:

• No licensed combination product exists in the UK

• Any combination use would be considered experimental and is not supported by current evidence

• Clinical decisions must be guided by a qualified healthcare professional with access to current trial data

Clinical Evidence and Trial Data Available to UK Patients

Retatrutide Phase 2 data showed approximately 24% mean body weight reduction at the highest dose over 48 weeks, but no published trial data exist for the specific cagrilintide–retatrutide combination.

The clinical evidence base for these agents, both individually and in combination, is still emerging. For retatrutide, Phase 2 trial data published in the New England Journal of Medicine (2023) demonstrated highly significant weight loss outcomes in adults with obesity (without type 2 diabetes). Participants receiving the highest dose (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks — results that exceeded those seen with currently approved agents at the time of publication. Improvements in cardiometabolic markers, including blood pressure, lipid profiles, and glycaemic control, were also observed.

For cagrilintide, Phase 2 data has shown meaningful weight loss when used as monotherapy, and the CagriSema combination (cagrilintide plus semaglutide) has entered Phase 3 trials under the REDEFINE programme by Novo Nordisk. Top-line results from REDEFINE 1 have been reported by Novo Nordisk; readers are encouraged to consult the most recent peer-reviewed publications or the company's regulatory announcements for verified efficacy figures, as data continue to be analysed and published.

Regarding the specific combination of cagrilintide with retatrutide, there is currently no published clinical trial data evaluating this pairing directly. UK patients should understand that:

• Available evidence is largely from Phase 2 studies with relatively short follow-up periods

• Long-term cardiovascular outcome data are not yet available for either agent

• Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA

UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities.

Safety Considerations, Side Effects, and MHRA Guidance

Both agents most commonly cause gastrointestinal side effects; serious risks include pancreatitis and gallbladder disease, and neither is licensed by the MHRA, so use outside clinical trials is not supported.

As with all investigational medicines, the safety profiles of cagrilintide and retatrutide are still being characterised through ongoing clinical trials. Based on available Phase 2 data, both agents share a side-effect profile broadly consistent with other medicines acting on metabolic hormone pathways, though the triple-agonist mechanism of retatrutide introduces some additional considerations.

Common side effects reported with retatrutide include:

• Nausea, vomiting, and diarrhoea (most frequent, particularly during dose escalation)

• Decreased appetite

• Constipation

• Injection site reactions

• Mild increases in heart rate

Cagrilintide has demonstrated a generally well-tolerated profile, with gastrointestinal symptoms also being the most commonly reported adverse effects.

Important safety warnings — seek urgent medical attention if you experience:

• Severe or persistent abdominal pain, which may radiate to the back — this could indicate pancreatitis, a serious but rare risk associated with GLP-1–based therapies as a class

• Right upper quadrant pain, fever, or jaundice — these may suggest gallbladder disease, another class-associated risk

• Signs of dehydration (dizziness, reduced urine output, extreme thirst) resulting from severe vomiting or diarrhoea, which can affect kidney function

Pregnancy and breastfeeding: Use of GLP-1–based therapies and related investigational agents is not recommended during pregnancy or breastfeeding. Women of childbearing potential should discuss contraception and pregnancy planning with their clinician before participating in any trial involving these medicines.

Hypoglycaemia: Whilst these agents are not expected to cause low blood sugar on their own, people with diabetes who are also taking insulin or sulfonylureas may be at increased risk of hypoglycaemia. Clinician-led dose adjustments of existing diabetes medicines may be required.

Of particular clinical importance with retatrutide is its glucagon receptor agonism. Preclinical signals regarding potential effects on thyroid C-cells (observed with GLP-1 agonists as a class), as well as theoretical questions about bone metabolism and cardiovascular function, are being monitored in ongoing trials. These remain areas of investigation in humans and should not be interpreted as established risks at this stage.

The MHRA has not issued specific guidance on cagrilintide or retatrutide as neither is currently licensed in the UK. Patients should not attempt to source these agents outside of regulated clinical trial settings. If you experience any unexpected symptoms whilst participating in a trial, you should:

• Contact your trial coordinator immediately, as trial participants must report adverse events through their study team

• Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk if appropriate

• Seek urgent medical attention if symptoms are severe

Current Availability and Regulatory Status in the UK

Neither cagrilintide nor retatrutide holds MHRA marketing authorisation in the UK; both remain in clinical development, and their specific combination does not exist as a registered investigational product.

Neither cagrilintide nor retatrutide is currently approved for clinical use in the United Kingdom. As of the time of writing, both agents remain in clinical development and have not received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA).

Retatrutide is being developed by Eli Lilly and Company, which has indicated plans to submit regulatory applications following the completion of Phase 3 trials. The MHRA will conduct its own independent benefit-risk assessment before any licence could be granted. Similarly, cagrilintide is being developed by Novo Nordisk, primarily as part of the CagriSema combination, with regulatory submissions anticipated once Phase 3 data are fully analysed and published.

The specific combination of cagrilintide with retatrutide does not currently exist as a named investigational product or registered clinical trial programme. Patients encountering online sources or private clinics offering this combination should exercise significant caution, as:

• Unregulated supply of investigational peptides carries serious safety risks

• Quality, purity, and dosing of unlicensed products cannot be guaranteed

• Use outside of a clinical trial setting is not supported by current evidence or regulatory frameworks

For those seeking access to obesity treatments within a safe and monitored environment, NICE-approved pathways for existing licensed therapies remain the appropriate starting point. NICE has issued technology appraisals for semaglutide 2.4 mg (Wegovy) for weight management (TA875) and for tirzepatide (Mounjaro) for managing overweight and obesity, each with defined eligibility criteria. Specialist referral is available through NHS Tier 3 and Tier 4 weight management services for those who meet the relevant thresholds.

Speaking to a UK Healthcare Professional About These Treatments

Patients interested in these treatments should speak to their GP or an obesity medicine specialist, who can assess eligibility for licensed therapies or clinical trials via NHS Tier 3 weight management services.

If you are interested in emerging obesity treatments such as cagrilintide, retatrutide, or potential combination approaches, the most appropriate first step is to speak with your GP or a specialist in obesity medicine. A healthcare professional can assess your individual clinical circumstances, review your current medications for potential interactions, and advise on whether you may be eligible for existing licensed treatments or clinical trial participation.

When attending an appointment, it may be helpful to:

• Bring a list of your current medications, including any supplements or over-the-counter products

• Discuss your weight history and previous treatment attempts, including any prior use of GLP-1 agonists

• Ask specifically about clinical trial eligibility, as some NHS trusts and academic centres are actively recruiting for obesity-related studies

• Raise any concerns about online sources offering unlicensed peptides, so your clinician can provide appropriate safety guidance

Your GP can refer you to NHS Tier 3 specialist weight management services if you meet the relevant criteria. Referral thresholds are broadly guided by NICE but may vary according to local NHS Integrated Care System (ICS) policies; your clinician will apply the criteria relevant to your area. NICE guidance on the assessment and management of overweight and obesity in adults (currently CG189 and associated updates) provides the overarching framework, alongside the technology appraisals for semaglutide 2.4 mg (TA875) and tirzepatide for weight management, which set out the eligibility criteria for these licensed medicines.

It is entirely reasonable to ask your healthcare professional about the latest evidence on investigational agents. However, patient safety must remain the priority. Treatments obtained outside of regulated NHS or clinical trial pathways — including unlicensed peptides purchased online — carry unpredictable risks and should be avoided. Staying informed through reputable sources such as the NHS website, NICE (nice.org.uk), and the MHRA (gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency) will help you make safe and well-informed decisions about your care.

Frequently Asked Questions